 |
217 Diseases |  |
230 Trials |
|
230 Trials |  |
3979 News |  |
| «12...2627282930313233343536...5051» |
- || fluorouracil / Generic mfg., doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Review, Journal: Cognitive impairment after cytotoxic chemotherapy. (Pubmed Central) - Apr 9, 2020
Patients mainly received combinations of 5-fluorouracil, epirubicin, cyclophosphamide, doxorubicin, and taxanes (FEC/FEC-T)...Of these, 2 studies investigated patients with colon cancer receiving 5-fluorouracil and oxaliplatin (FOLFOX)...There is evidence that certain chemotherapy regimens cause PCCI more frequently than others as evidenced by 21 out of 23 studies in breast cancer patients (mainly FEC-T), whereas 2 out of 3 studies with colon cancer patients (FOLFOX) did not observe significant changes. Further studies are needed defining patient cohorts by treatment protocol in addition to cancer type to elucidate the effects of individual cytotoxic drugs on cognitive functions.
- | epirubicin / Generic mfg.
Journal: Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression. (Pubmed Central) - Apr 9, 2020
Further, TMP reverted epirubicin resistance by inhibiting JAK2/STAT3 signaling and decreasing FGG expression...Our data collectively indicated that FGG was an independent detrimental factor for anthracycline based chemotherapy for breast cancer patients. TMP was a novel chemosensitizer for FGG-induced anthracycline chemoresistance in breast cancer treatment.
- oxaliplatin / Generic mfg., fluorouracil / Generic mfg.
Hepatic arterial infusion chemotherapy (HAIC) using oxaliplatin plus 5-fluorouracil versus transarterial chemoembolization/embolization (TACE/TAE) for advanced hepatocellular carcinoma with major portal vein tumor thrombosis (Room: 3AB ) - Apr 8, 2020 - Abstract #SIR2020SIR_38;
In the TACE/TAE group (n=24), an emulsion of epirubicin (40-60 mg) and lipiodol was administered followed by particles, or embosphere alone embolization every 3–4 weeks. HAIC may significantly improve overall survival and provide better tumor control with wild side effect in advanced HCC with major PVTT but with well reserved liver function compared with TACE/TAE treatment.
- | carboplatin / Generic mfg., capecitabine / Generic mfg.
New P3 trial: NBG-19-01: NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC (clinicaltrials.gov) - Apr 5, 2020
P3, N=820, Recruiting, Sponsor: Lund University Hospital
- || Clinical, Journal: The Efficacy and Safety of Modified Docetaxel, Cisplatin, and 5-Fluorouracil Vs. Epirubicin, Oxaliplatin, and Capecitabine Regimen in the Advanced Gastric Cancer: A Randomized Controlled Clinical Trial. (Pubmed Central) - Apr 3, 2020
HAIC may significantly improve overall survival and provide better tumor control with wild side effect in advanced HCC with major PVTT but with well reserved liver function compared with TACE/TAE treatment. It seems that both m-DCF and EOX regimens are similar in terms of survival and toxicity and are recommended as first-line treatment for advanced gastric cancer with respect to the patient's status.
- || fluorouracil / Generic mfg.
Clinical, Journal: Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy. (Pubmed Central) - Apr 2, 2020
P2
Low baseline VFA and SMA, as well as the severe loss of VFA and SMA predict poor prognosis for MGC patients treated by EOF regimen. In patients with severe loss of VFA and/or SMA after 2-cycle chemotherapy, the decision of subsequent chemotherapy should be made after deliberate consideration.
- || epirubicin / Generic mfg.
Clinical, Journal: CD44-Specific A6 Short Peptide Boosts Targetability and Anticancer Efficacy of Polymersomal Epirubicin to Orthotopic Human Multiple Myeloma. (Pubmed Central) - Mar 31, 2020
A6-PS-EPI displays remarkable targeting ability to orthotopic LP-1 MM, causing depleted bone damage and striking survival benefits compared to nontargeted PS-EPI. Overall, A6-PS-EPI, as a simple and intelligent nanotherapeutic, demonstrates high potential for clinical translation.
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion: Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer (clinicaltrials.gov) - Mar 31, 2020
P2, N=50, Completed, Sponsor: Yale University
Overall, A6-PS-EPI, as a simple and intelligent nanotherapeutic, demonstrates high potential for clinical translation. Active, not recruiting --> Completed
- || Herceptin (trastuzumab) / Roche, paclitaxel / Generic mfg., docetaxel / Generic mfg.
Clinical, P2 data, Journal: Phase II Study of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy for Operable Breast Cancer Patients (N-1 Study). (Pubmed Central) - Mar 29, 2020
It is also expected to be effective even in patients with luminal type disease. However, further randomized control trials are needed to ascertain whether pCR can contribute to favorable outcomes.
- || doxorubicin hydrochloride / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Desmoplastic small round cell tumors: Multimodality treatment and new risk factors. (Pubmed Central) - Mar 29, 2020
The VAIA scheme showed best outcome. Maintenance therapy should be investigated further.
- | epirubicin / Generic mfg.
Journal: Terminating the renewal of tumor-associated macrophages: a sialic acid-based targeted delivery strategy for cancer immunotherapy. (Pubmed Central) - Mar 29, 2020
Given this, a sialic acid-octadecylamine conjugate (SA-ODA) was synthesized and then modified on the surface of liposomal epirubicin (EPI-SAL) as a potent tumor-targeting delivery strategy...Thus, an SA-based targeted delivery strategy effectively interdicted the generation of TAMs. Our research provides the feasibility of the SA-ODA decorated liposome as an active carrier for cancer immunotherapy.
- || doxorubicin hydrochloride / Generic mfg.
Review, Journal: A systematic review on hepatoprotective activity of quercetin against various drugs and toxic agents: Evidence from preclinical studies. (Pubmed Central) - Mar 29, 2020
In this review, we provide an overview of the possible mechanisms by which quercetin reduced the hepatotoxicity of different hepatotoxicants. This will help the toxicologists, pharmacologists, and chemists to develop new safer pharmaceutical products with quercetin and other hepatotoxicants.
- || Clinical, Journal: Correlation of HER2 codon 655 polymorphism with cardiotoxicity risk in Chinese HER2-positive breast cancer patients undergoing epirubicin/cyclophosphamide followed by docetaxel plus trastuzumab adjuvant chemotherapy. (Pubmed Central) - Mar 28, 2020
Logistic regression analysis further revealed that HER2 codon 655 A>G, smoking and baseline cTnI were independent predictive factors for increased cardiotoxicity risk. In conclusion, HER2 codon 655 A>G was an independent predictive factor for increased cardiotoxicity risk in HER2-positive breast cancer patients undergoing EC-D-T adjuvant chemotherapy.
- | Opdivo (nivolumab) / BMS
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date, Metastases: ImmunoSarc: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas (clinicaltrials.gov) - Mar 26, 2020
P1/2, N=270, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
In conclusion, HER2 codon 655 A>G was an independent predictive factor for increased cardiotoxicity risk in HER2-positive breast cancer patients undergoing EC-D-T adjuvant chemotherapy. Active, not recruiting --> Recruiting | N=108 --> 270 | Trial completion date: May 2020 --> Sep 2022 | Trial primary completion date: May 2020 --> Sep 2022
- || cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo
Clinical, Journal: Clinical characteristics, treatment patterns and outcomes of patients older than 80 years diagnosed with DLBCL in China over a 10-year period. (Pubmed Central) - Mar 26, 2020
High response rate was concluded on very elderly DLBCL patients (≥ 80 years old) with reduced-dose R-CHOP. However, the very elderly patients with NCCN-IPI score ≥ 5 would lead to poor outcome.
- || capecitabine / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis. (Pubmed Central) - Mar 24, 2020
Conclusions Perioperative treatment in radically resected gastric cancer patients after D2 lymphadenectomy was beneficial in stages IIIb and IIIc. The effects of perioperative treatment in lower stages could be negated by the effects of the radical surgery in lower stages and in higher stages by the biology of the disease.
- | epirubicin / Generic mfg.
Journal: Elevated release of inflammatory but not sensory mediators from the urothelium is maintained following epirubicin treatment. (Pubmed Central) - Mar 24, 2020
Epirubicin treatment induces several transient changes in urothelial function. However, the increased secretion of inflammatory cytokines (IL-6 and IL-8) is sustained and these mediators may be involved in the pathophysiology of bladder toxicity following intravesical epirubicin treatment.
- || Clinical, Journal: Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. (Pubmed Central) - Mar 24, 2020
Docetaxel, cyclophosphamide and trastuzumab might be an option for primary systemic therapy in human epidermal growth factor receptor-2-positive early breast cancer. A larger confirmatory study is necessary.
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date: Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy (clinicaltrials.gov) - Mar 23, 2020
P3, N=290, Recruiting, Sponsor: RenJi Hospital
A larger confirmatory study is necessary. Trial primary completion date: Dec 2019 --> Jun 2020
- | Journal: Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs. (Pubmed Central) - Mar 23, 2020
In addition, KH-1 covalently conjugated with anthracycline anticancer agent, epirubicin, integrates the advantages of both chemosensitization function and improved intracellular drug delivery in a single system and takes effect on the same cell. Therefore, in the present study, we have provided mechanistic demonstration that crosslinking of surface receptors can be leveraged to elicit chemosensitization.
- || fluorouracil / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Effects of neoadjuvant chemotherapy on respiratory function in patients with breast cancer. (Pubmed Central) - Mar 21, 2020
However, there was no significant correlation between the changes in these PFTs parameters and the results of the EORTC QLQ-C30 (P>0.05). Neoadjuvant chemotherapy can reduce lung diffusion function and quality of life in females with breast cancer.
- | fluorouracil / Generic mfg., paclitaxel / Generic mfg.
Journal, IO Biomarker: Role of Bcl-2 on drug resistance in breast cancer polyploidy-induced spindle poisons. (Pubmed Central) - Mar 21, 2020
Expression of the Bcl-2 family members, for example FBW7 and MCL-1, plays a key role in apoptosis and the cell escape process that forms polyploid cells. However, Bcl-2 silencing has different reversal effects on different anti-tumor drugs, which requires further investigation.
- | Preclinical, Journal: In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. (Pubmed Central) - Mar 19, 2020
However, Bcl-2 silencing has different reversal effects on different anti-tumor drugs, which requires further investigation. This in vitro analysis indicates the suitability of our novel admixtures containing less toxic drug equivalents in a single infusion bag for clinical application.
- || epirubicin / Generic mfg.
Agree we gave Epirubicin (Twitter) - Mar 19, 2020
- | epirubicin / Generic mfg.
Journal: Convection-Enhanced Delivery of a Virus-Like Nanotherapeutic Agent with Dual-Modal Imaging for Besiegement and Eradication of Brain Tumors. (Pubmed Central) - Mar 18, 2020
coli) for epirubicin (EPI) loading, cell-penetrating peptide (CPP) modification, and Ga-DOTA labeling to form a positron emission tomography (PET)-fluorescence dual-imaging monitored virus-like nanotherapeutic agent (Ga-DOTA labeled EPI@CPP-gVLPs) combined with CED for brain tumor therapy and image tracking...In vivo delivery of the Ga-DOTA-labeled EPI@CPP-gVLPs through CED demonstrated that the median survival was prolonged to over 50 days when the mice received two administrations (once per week) compared with the control group (median survival: 26 days). The results clearly indicated that a combination of Ga-DOTA-labeled EPI@CPP-gVLPs and CED can serve as a flexible and powerful synergistic treatment in brain tumors without evidence of systemic toxicity.
- | letrozole / Generic mfg., everolimus / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer (clinicaltrials.gov) - Mar 18, 2020
P2, N=40, Active, not recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The results clearly indicated that a combination of Ga-DOTA-labeled EPI@CPP-gVLPs and CED can serve as a flexible and powerful synergistic treatment in brain tumors without evidence of systemic toxicity. Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
- | cyclophosphamide intravenous / Generic mfg.
Journal: Effects of in-utero exposure to chemotherapy on fetal brain growth. (Pubmed Central) - Mar 18, 2020
Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> May 2020 | Trial primary completion date: Dec 2019 --> Mar 2020 Prenatal exposure to anthracycline/cyclophosphamide-based chemotherapy does not impact fetal brain growth, thus supporting the idea that oncological treatment in pregnant women seems to be feasible and safe for the fetus.
- | Clinical Trial,Phase III, Journal: Pembrolizumab for Early Triple-Negative Breast Cancer. (Pubmed Central) - Mar 17, 2020
P3
Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among those who received placebo plus neoadjuvant chemotherapy. (Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.).
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Trial completion, Trial completion date, BRCA Biomarker, PARP Biomarker: GeparOla: Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (clinicaltrials.gov) - Mar 17, 2020
P2, N=107, Completed, Sponsor: German Breast Group
(Funded by Merck Sharp & Dohme [a subsidiary of Merck]; KEYNOTE-522 ClinicalTrials.gov number, NCT03036488.). Recruiting --> Completed | Trial completion date: Nov 2018 --> Feb 2020
- | docetaxel / Generic mfg., epirubicin / Generic mfg., gemcitabine / Generic mfg.
Journal: MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. (Pubmed Central) - Mar 14, 2020
In addition, miR-512-3p overexpression significantly inhibited tumor growth in vivo. Collectively, our data suggest that miR-512-3p is a significant regulator of tumorigenesis and drug resistance in breast cancer and provides evidence that miR-512-3p may represent a promising target for breast cancer therapy.
- || fluorouracil / Generic mfg., Ilaxten (bilastine) / Otsuka, cyclophosphamide intravenous / Generic mfg.
Clinical, Retrospective data, Journal: The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial. (Pubmed Central) - Mar 13, 2020
In the Italian Breast Cancer Intergroup Studies (IBIS) 3 phase III trial, we compared cyclophosphamide, methotrexate, 5-fluorouracil (CMF) alone to sequential epirubicin/CMF regimens in patients with rapidly proliferating early breast cancer (RPEBC)...We analyzed 466 patients with hormone-receptor-positive RPEBC receiving sequential epirubicin/CMF regimens followed by tamoxifen, and for whom the status of ER and PgR was available...Upon multivariate analysis, only tumor size, nodal status, and PgR were independent prognostic factors. Our results highlight the independent prognostic relevance of PgR expression in patients with hormone-receptor-positive RPEBC treated with adjuvant chemotherapy and endocrine therapy, where the definition of prognostic subgroups is still a major need.
- | Enrollment change, Trial termination: COMPETE: Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients (clinicaltrials.gov) - Mar 11, 2020
P3, N=21, Terminated, Sponsor: Ruijin Hospital
Our results highlight the independent prognostic relevance of PgR expression in patients with hormone-receptor-positive RPEBC treated with adjuvant chemotherapy and endocrine therapy, where the definition of prognostic subgroups is still a major need. N=252 --> 21 | Recruiting --> Terminated; Hard to enroll expected number of eligible patients.
- || Decadron (dexamethasone) / Merck (MSD), methylprednisolone oral / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Comparison of Various Hematopoietic Stem Cell Mobilization Regimens in Patients with Lymphoma and Myeloma. (Pubmed Central) - Mar 10, 2020
The results of this study provide information on the effectiveness of different stem cell mobilization regimens. Although no significant difference was determined between the three major chemotherapy regimens, the ESHAP regimen appears to be the preferred treatment regimen for stem cell mobilization in selected lymphomas.
- | cyclophosphamide / Generic mfg., docetaxel / Generic mfg., epirubicin / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date: ELEGANT: Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer (clinicaltrials.gov) - Mar 10, 2020
P4, N=304, Completed, Sponsor: Ruijin Hospital
Although no significant difference was determined between the three major chemotherapy regimens, the ESHAP regimen appears to be the preferred treatment regimen for stem cell mobilization in selected lymphomas. Recruiting --> Completed | Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020
- | Trial completion date, Trial primary completion date, Metastases: Tumorspheres Colrec: Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 10, 2020
P2, N=90, Recruiting, Sponsor: Vejle Hospital
Recruiting --> Completed | Trial completion date: Sep 2019 --> Mar 2020 | Trial primary completion date: Sep 2019 --> Mar 2020 Trial completion date: Dec 2020 --> Jun 2022 | Trial primary completion date: Feb 2020 --> Aug 2021
- |||||||||| Hansizhuang (serplulimab) / Fosun Pharma
New P3 trial, Combination therapy: to Evaluate Efficacy and Safety of HLX10 in Combination With Chemotherapy Versus Placebo in Combination With Chemotherapy as Neoadjuvant Therapy and HLX10 Versus Placebo as Adjuvant Therapy in Patients With Triple Negative Breast Cancer (TNBC) (clinicaltrials.gov) - Mar 10, 2020
P3, N=522, Not yet recruiting, Sponsor: Shanghai Henlius Biotech
- doxorubicin hydrochloride / Generic mfg.
Validation of a Cardio-Oncology Risk-Management Algorithm for a New Cardio-Oncology Service and Evaluation of Cardiotoxicity Trends in Breast Cancer Patients () - Mar 9, 2020 - Abstract #HOPA2020HOPA_399;
This is a retrospective chart review of adult, female breast cancer patients who initiated a new chemotherapy regimen containing at least one of the following cardiotoxic chemotherapy agents: doxorubicin, epirubicin, trastuzumab, pertuzumab, ado-trastuzumab emtansine, eribulin, lapatinib, ribociclib, fluorouracil, and capecitabine between January 1, 2017 and December 31, 2017. Pending
- | gemcitabine / Generic mfg.
Journal: Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence. (Pubmed Central) - Mar 8, 2020
In conclusion, gemcitabine intravesical chemotherapy group was significantly related to a lower rate of recurrence, progression and treatment failure. Gemcitabine could be considered as a choice for these patients who are not suitable for BCG.
- | Journal: EpiCO (epirubicin, cyclophosphamide and vincristine) as treatment for extrapulmonary high-grade neuroendocrine neoplasms. (Pubmed Central) - Mar 8, 2020
Due to a better toxicity profile, doxorubicin was replaced by epirubicin, resulting in the combination of epirubicin, cyclophosphamide and vincristine (abbreviated as EpiCO or CEV).In analogy to SCLC, selected patients with high-grade NEN were treated with the EpiCO regimen in second line (or in one patient first line) at our center. In this report we present the retrospective series of 5 cases with metastatic high-grade GEP/CUP NEN/MiNEN who received chemotherapy according to this protocol.
- doxorubicin hydrochloride / Generic mfg.
[VIRTUAL] DISEASE BURDEN ASSOCIATED WITH PROGRESSION IN PATIENTS WITH HIGH-GRADE NON-MUSCLE INVASIVE BLADDER CANCER RECEIVING BLADDER PRESERVING THERAPIES AFTER ADEQUATE BCG INDUCTION- A SEER-MEDICARE DATABASE STUDY () - Mar 8, 2020 - Abstract #ISPOR2020ISPOR_497;
CONCLUSIONS : The disease burden of progression among HG NMIBC patients receiving currently available BPT following adequate BCG induction is substantial, indicating urgent unmet need. Novel effective BPTs are needed in this patient population.
- || carboplatin / Generic mfg., epirubicin / Generic mfg.
Clinical, Journal: Three cases of advanced cutaneous squamous cell carcinoma treated with a combination of carboplatin and epirubicin. (Pubmed Central) - Mar 7, 2020
Novel effective BPTs are needed in this patient population. No abstract available
- || fluorouracil / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. (Pubmed Central) - Mar 7, 2020
In this prospective-retrospective analysis, patients with Her2-enriched breast cancer derived substantial benefit from anthracycline chemotherapy whereas anthracyclines are not an essential component of chemotherapy for patients with luminal subtypes. The benefit of CEF vs. CMF correlated with increasing ROR Score.
- || fluorouracil / Generic mfg., cyclophosphamide intravenous / Generic mfg.
Clinical, Journal: Dose tailoring of adjuvant chemotherapy for breast cancer based on hematologic toxicities: Further results from the prospective PANTHER study with focus on obese patients. (Pubmed Central) - Mar 5, 2020
P3
Dose tailoring is a feasible strategy which can potentially improve outcomes in obese patients without increasing toxicity and should be pursued in further clinical studies. NCT00798070.
- | carboplatin / Generic mfg., paclitaxel / Generic mfg.
New P3 trial: Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (clinicaltrials.gov) - Mar 5, 2020
P3, N=808, Recruiting, Sponsor: Fudan University
- || Clinical, Observational data, Journal: Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. (Pubmed Central) - Mar 4, 2020
This is the second study that compared a 0.25 mg dose of palonosetron with first-generation setron in triplet antiemetic prophylaxis in cancer patients receiving HEC. We could not find meaningful statistical differences between two arms, regarding CR rate on acute and delayed CINV.
- | epirubicin / Generic mfg.
Journal: Development and validation of a high-performance liquid chromatographic method with a fluorescence detector for the analysis of epirubicin in human urine and plasma, and its application in drug monitoring. (Pubmed Central) - Mar 4, 2020
The obtained results confirmed that the optimized and validated LC-FL method can be successfully used in drug monitoring therapy, pharmacokinetic and clinical studies. Moreover, the current work is also drawing attention to the relatively high level of epirubicin in the patient urine, which requires compliance with the safety rules in contact with this biological fluid by both medical staff and others, e.g. family members.
- || Trial completion date, Trial primary completion date, Compliance: PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy (clinicaltrials.gov) - Mar 4, 2020
P2, N=75, Recruiting, Sponsor: PhytoHealth Corporation
Moreover, the current work is also drawing attention to the relatively high level of epirubicin in the patient urine, which requires compliance with the safety rules in contact with this biological fluid by both medical staff and others, e.g. family members. Trial completion date: Aug 2020 --> Jun 2021 | Trial primary completion date: Apr 2020 --> Dec 2020
- epirubicin / Generic mfg.
Epirubicin-induced cardiotoxicity: use of myocardial strain for early detection of left ventricular dysfunction before LVEF declines (Exhibition area) - Mar 4, 2020 - Abstract #ESMOBC2020ESMO_BC_417;
- | epirubicin / Generic mfg.
Biomarker, Journal: Long non-coding RNA NONHSAT101069 promotes epirubicin resistance, migration, and invasion of breast cancer cells through NONHSAT101069/miR-129-5p/Twist1 axis. (Pubmed Central) - Mar 2, 2020
Twist1 was a direct downstream protein of NONHSAT101069/miR-129-5p axis in BC cells. To conclude, NONHSAT101069 was upregulated in BC tissues and promoted epirubicin resistance, migration and invasion of BC cells via regulation of NONHSAT101069/miR-129-5p/Twist1 axis, highlighting its potential as an oncogene and a therapeutic biomarker for BC.
- | doxycycline / Generic mfg.
Journal: Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance. (Pubmed Central) - Mar 2, 2020
We showed that metastatic RCC 3D spheroids supported with ECM are a useful model to determine the cancer cell growth characteristics that are not found in adherent 2D cultures. Due to the more complex architecture, spheroids may mimic in vivo micrometastases and may be more appropriate to investigate novel drug candidate responses, including the direct effects of tyrosine kinase inhibitor activity against RCC cells.